Does inhibiting the RAAS with ACE ARB MRA cause hyperkalemia in patients on dialysis

Sharing is caring!

Does inhibiting the RAAS with ACE ARB MRA cause hyperkalemia in patients on dialysis

Does inhibiting the renin-angiotensin aldosterone system (RAAS) with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists (MRA) cause hyperkalemia in patients on dialysis?

End-stage kidney disease (ESKD) patients on dialysis may be oliguric or anuric and hence do not depend on kidney excretion of potassium. These patients depend on dialysis and restriction of oral intake of potassium to maintain acceptable levels. Recent evidence from small-sized studies has shown that administration of low-dose MRA provides cardioprotective effects in both hemodialysis and peritoneal dialysis patients without significantly increasing the risk of hyperkalemia. MRA may improve mortality in ESKD dialysis patients, but larger studies are needed to establish safe protocols for their use in dialysis patients.

Sharing is caring!

You cannot copy content of this page

15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856
Scroll to Top